US2022031608A1PendingUtilityA1

Compositions and methods for the treatment of presbyopia

Assignee: LENZ THERAPEUTICS INCPriority: Aug 28, 2013Filed: Oct 15, 2021Published: Feb 3, 2022
Est. expiryAug 28, 2033(~7.1 yrs left)· nominal 20-yr term from priority
Inventors:Gerald Horn
A61K 47/26A61K 47/34A61K 45/06A61K 31/4409A61P 27/10A61K 47/38A61K 47/02A61K 47/10A61K 31/439A61K 47/32A61K 9/08A61K 9/0048
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating presbyopia comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine. 
     
     
         2 . The method of  claim 1 , wherein aceclidine is at a concentration from about 0.25% to about 2.5% w/v, wherein w/v denotes weight by total volume of the composition. 
     
     
         3 . The method of  claim 1 , wherein aceclidine is at a concentration from about 0.75% to about 2.5% w/v. 
     
     
         4 . A method of treating presbyopia comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine and a viscosity agent. 
     
     
         5 . The method of  claim 4 , wherein aceclidine is at a concentration from about 0.25% to about 2.5% w/v, wherein w/v denotes weight by total volume of the composition. 
     
     
         6 . The method of  claim 4 , wherein aceclidine is at a concentration from about 0.75% to about 2.5% w/v. 
     
     
         7 . A method of treating presbyopia comprising administering a composition comprising aceclidine and one or more nonionic surfactants to a subject in need thereof. 
     
     
         8 . The method of  claim 7 , wherein aceclidine is at a concentration from about 0.25% to about 2.5% w/v, wherein w/v denotes weight by total volume of the composition. 
     
     
         9 . The method of  claim 7 , wherein aceclidine is at a concentration from about 0.75% to about 2.5% w/v. 
     
     
         10 . A method of treating low regular astigmatism, low or high irregular astigmatism, keratoconic ectasia, night vision halos/starbursts, night vision reduced contrast, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine.

Join the waitlist — get patent alerts

Track US2022031608A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.